• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effects of TheraMax on influenza virus infections in cell culture and in mice

tetano

Editor, Senior Moderator
Antivir Chem Chemother. 2011 Jul 4;21(6):231-7.
Effects of TheraMax on influenza virus infections in cell culture and in mice.
Smee DF, Hurst BL, Wong MH.
Source

Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA. don.smee@usu.edu.
Abstract
BACKGROUND:

Limited in vivo studies in the scientific literature suggest that components of green tea and elderberry may be beneficial in treating influenza virus infections. They are thought to act by blocking virus adsorption to cells. TheraMax(?) is a proprietary medication administered by nasal spray that contains both green tea and elderberry extracts that was evaluated for antiviral activity.
METHODS:

TheraMax was tested by dilution in Madin-Darby canine kidney cell cultures in standard viral cytopathic effect (CPE) inhibition and virucidal assays against eight influenza A and B strains. It was also administered intranasally to mice to determine protective activity compared to oral oseltamivir against an influenza A/NWS/33 (H1N1) infection.
RESULTS:

In cell culture assays, TheraMax was found to inhibit viral CPE by 50% at a 1:20 dilution for seven of the eight virus strains, with no virucidal activity at 1:2 dilution. The undiluted product was administered to anaesthetized mice twice daily for 4 days starting 2 h before or 12 h after infection. Alternatively, TheraMax and virus were combined for treatment and infection. Oseltamivir was given orally twice daily for 5 days at 10 mg/kg/day starting at -2 h. TheraMax (combined directly with virus) and oseltamivir each prevented death and curtailed weight loss during the infection, and improved lung haemorrhage scores on day 6. TheraMax starting at -2 h or 12 h significantly delayed death by >2 days and reduced lung haemorrhage scores, but most animals died.
CONCLUSIONS:

These combined results indicate that TheraMax delayed symptoms during animal infections, likely through blocking of virus adsorption.

PMID:
21730370
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/21730370
 
Back
Top Bottom